AbbVie announced Q3 2025 revenue of USD 15.8 billion representing 9.1% growth, with the 9-month total reaching USD 44.5 billion driven by immunology portfolio contributions of USD 21.8 billion, including Skyrizi (risankizumab) sales of USD 12.6 billion and Rinvoq (upadacitinib) revenue of USD 5.9 billion. The neuroscience division grew 20.3% to USD 7.8 billion led by migraine therapies Ubrelvy (Ubrogepant) and Qulipta (atogepant), while the oncology segment increased 2.6% to USD 5.0 billion with Venclexta (venetoclax) surpassing Imbruvica (ibrutinib) as top-selling haematology product. The aesthetics and eye care divisions declined 7.8% and 4.2% respectively, reflecting market competition and procedure volume fluctuations. Recent acquisitions by the company include Capstan Therapeutics, adding an anti-CD19 CAR-T therapy and targeted lipid nanoparticle platform, alongside the bretisilocin antidepressant enhancing neuroscience pipeline. AbbVie's R&D focus includes a (ADC)PD-1/VEGF bispecific antibody (BsAb), complementing the company's antibody-drug conjugate (ADC) portfolio for next-generation immuno-oncology leadership. Rinvoq label expansions include a recent US supplemental new drug application (sNDA) approval for ulcerative colitis (UC) and Crohn's disease (CD), with Phase III data demonstrating efficacy in alopecia areata and nonsegmental vitiligo, supporting continued growth trajectory across autoimmune indications.